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Abstract
OBJECTIVE: To study the effects of Xixin decoction
(XXD) on O-linked N-acetylglucosamine (O-GlcNAc)
glycosylation of tau proteins in rat brain with spo-
radic Alzheimer disease (SAD), and discuss its possi-
ble mechanism on prevention and treatment of
SAD.
METHODS: The rat model of SAD was established
by intracerebroventricular injection of streptozoto-
cin. The specific pathogen free male Sprague-Daw-
ley rats were randomly divided into sham-opera-
tion group (S), model group (M), donepezil group
(D), XXD at a low dose group (XL), XXD at a medium
dose group (XM) and XXD at a high dose group
(XH). After treatment and praxiology test, immuno-
histochemistry and western blotting were used to
detect O-GlcNAc glycosylation level of tau proteins
in rat brain with SAD. O-GlcNAc glycosylation and
expression of tau proteins were detected by
O-GlcNAc-specific antibodies RL2 and CTD110.6.
RESULTS: O-GlcNAc glycosylated proteins enriched
by succinylated wheat germ agglutinin significant-
ly improved in the hippocampus of SAD rats. The
differences were statistically significant among
XXD groups (P<0.05, P<0.01), while no obvious dif-
ferences were observed between D group and M
group (P>0.05).
CONCLUSION: XXD can significantly improve
O-GlcNAc glycosylation level of tau proteins in the
hippocampus of SAD rats, which maybe inhibit hy-
perphosphorylation of tau proteins on key sites
and its toxicity, and prevent the pathological pro-
cess of SAD.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Protein phosphorylation and glycosylation modifica-
tion on O-linked N-acetylglucosamine (O-GlcNAc)
are known as two major ways of modification after pro-
tein translation. Several studies showed a negative cor-
relation and balancing mechanism between these two
modifications.1 This bears similarity with the balance
between Yin and Yang in Traditional Chinese Medicine
which can be interpreted as adjustment between Yin
and Yang.2 Breaking of this balance would lead to intra-
cellular neurofibrillary tangles (NFT), a histopathologi-
cal change of Alzheimer disease caused by abnormal hy-
perphosphorylation of neural tubulin tau.3
In this study, we investigated the effects of Xixin decoc-
tion (XXD) on O-GlcNAc glycosylation of tau pro-
teins in rat brain with sporadic Alzheimer disease
(SAD),4 and explore its possible mechanism on prohibi-
tion of abnormal hyperphosphorylation of neural tubu-
lin tau in SAD brain and prevention of SAD progres-
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sion via glycosylation modification on O-GlcNAc.
MATERIALS ANDMETHODS
Animals and grouping
Eighty-four specific pathogen free male Sprague-Daw-
ley rats weighting (270±20) g, purchased from Experi-
mental Animal Center of The Fourth Military Medical
University (Certificate No. 0034642) were randomly
divided into sham-operation group (S), model group
(M), donepezil group (D), XXD at a low dose group
(XL), XXD at a medium dose group (XM), and XXD
at a high dose group (XH), 14 rats in each group. The
animals were fed in barrier system (Approval No.
SYXK2007-2010). During the experiment, rats were
free to take in water and food. The temperature was
kept at 22℃-26℃ and humidity at 30%-40%. The ex-
perimental procedures and the animal use and care pro-
tocols were approved by the Committee on Ethical Use
of Animals of Shaanxi University of Chinese Medicine.
Medicines and reagents
XXD, with ingredients of Renshen (Radix Ginseng),
Banxia (Rhizoma Pinelliae), Fushen (Poria Cum Radix
Pini), Fuzi (Radix Aconiti Lateralis Preparata),
Shichangpu (Rhizoma Acori Tatarinowii) and some oth-
er Chinese herbs, was provided in the form of granules
by Sanjiu Medical and Pharmaceutical Co., Ltd. (Shen-
zhen, China) (Approval No. 0908032). Streptozotocin
was supplied by Merck and Co., Inc (Whitehouse Sta-
tion, NJ, USA) (Approval No. K0050). Donepezil was
purchased from Xi'an Haixin Pharmaceutical Co., Ltd.
(Xi'an, China) (Approval No. 091201).
Succinylated wheat germ agglutinin (sWGA), provided
by EY Laboratories (San Mateo, CA, USA), was ap-
plied in enrichment of O-GlcNAc glycosylated pro-
teins in the hippocampus, and was diluted at a ratio of
1∶400 during western blotting.
CTD110.6 primary antibody, purchased from Santa-
Cruz (Dallas, TX, USA), was used to detect
O-GlcNAc glycosylation level of tau proteins in the
hippocampus, and was diluted at a ratio of 1∶1000
during western blotting.
RL2 primary antibody, supplied by Pierce-ABR (Rock-
ford, IL, USA), was applied to detect O-GlcNAc glyco-
sylation level of tau proteins in the hippocampus, and
was diluted at a ratio of 1∶200 during immunohisto-
chemistry staining and 1∶1000 during western blot-
ting.
Model preparation
According to Sharma's method,5 rats were anesthetized
by 10% chloral hydrate before placed on the stereotax-
is instrument. Following routine disinfection of skin,
median sagittal incision was made in rats' skull and du-
ra mater was separated to expose endocranium. Except
for S group, 18 μL of streptozotocin was injected intra-
cerebroventricular via microinjector (before injection,
streptozotocin was dissolved in artificial cerebrospinal
fluid with the concentration of 25 mg/mL). Coordina-
tion was made according to The Rat Brain in Stereotax-
ic Coordinates.6 The same amount was injected for the
second time on day 3. For S group, same amount of ar-
tificial cerebrospinal fluid was injected instead of strep-
tozotocin.
Administration process
Medicine was administered from day 21 after the sec-
ond modeling. XXD granules were dissolved in double
distilled water at 60℃ and were further formulated in-
to high dose, medium dose and small dose (every 29 g
extract equals to 169 g of crude drug). Accordingly, the
administration doses of crude drug were as follows:
high dose of 30.42 g/kg-1·d-1, medium dose of 15.21 g/
kg-1·d-1 and small dose of 7.61 g/kg-1·d-1. Administra-
tion of donepezil was 0.92 mg/kg and given 7.5 mg/kg
per day by gavage. M and S groups were given the
same amount of double distilled water by gavage. Each
group received administration by gavage once per day
for 2 months.
Brain tissue sample treatment
After ethology test on rats' behaviors test applied in
Morris water maze,7 six rats from each group were ran-
domly selected to perform perfusion fixation. Rats
were anesthetized with 10% chloral hydrate (4.0 mL/
kg) via intraperitoneal injection. After anesthesia, rats
were laid in supine posture with four extended limbs
fixed. Rat's chest was opened to exposed heart and liv-
er. Catheter was rapidly plugged into ascending aorta
through left ventricle and fixed. Meanwhile, right auri-
cle was cut open. 100 mL of normal saline was infused
rapidly until the liver turned pale. When clear liquid
flew from right ventricle, 4% paraformaldehyde was in-
fused continuously for 30 min from fast to slow speed.
Then, rats were beheaded and their brains were taken
out before putting into stationary liquid. Samples were
made into paraffin-embedded sections after 24 h. Coro-
nal sections were sliced continuously after the present
of hippocampal CA1 region and put into 0.01M phos-
phate-buffered saline with Tween (PBST) solution for
immunohistochemical staining. For western blotting,
fresh hippocampus was taken out and placed into liq-
uid nitrogen for quick freezing before preserved in re-
frigerator at－70℃.
Immunohistochemical staining
Paraffin sections were deparaffinized with xylene. After
endogenous peroxidase activity was blocked with 3%
H2O2, sections were washed with distilled water, then
placed in citrate buffer (pH 6.0) for heat repairing of
antigen before washed with phosphate buffer solution
(PBS) (pH 7.4). Sections were sealed by dropping 5%
bull serum albumin at 37℃ for 20 min and superflu-
ous liquid was removed. Diluted primary antibody was
added overnight at 4℃ and washed with PBS. Then re-
lated second antibody was added for incubation 1 h at
37℃ and washed with PBS. Sections were added with
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dolichos biflorus agglutinin and kept for 5-30 min at
room temperature followed by incubation with strepta-
vidin-biotin working solution labeled by horseradish
peroxidase for 1 h at 37℃ . After hematoxylin staining
and dehydration in a graded series of alcohol, the sec-
tions were cleared in xylene and sealed with neutral bal-
asam.
Analysis of immunohistochemical staining: images of
brain slices in the same position of each rat's were col-
lected and analyzed via digital medical image analysis
system Motic Med 6.0. Positive cell counts, total area
of positive cells as well as integral optical density from
each group of image were recorded.
Western blot analysis
(a) Rats' hippocampal proteins were extracted; (b) con-
tent of hippocampal proteins was assessed using Fo-
lin-phenol reagent; (c) sodium dodecyl sulfate poly-
acrylamide gel electrophoresis; (d) translocation; (e) im-
mune response (add related second antibody diluted at
a ratio of 1∶1000 respectively); (f ) chemiluminescence
reaction: sip up PBST on the membrane and lay the
membrane on a clean plate with membrane protein on
the top. Put the membrane into intelligent camera ob-
scura with Syngene GBOX iChemi multi-functional
chemiluminescence gel imaging system. Mix the same
amount of luminescence liquid A and B and pour
them evenly on the membrane with pipettor for expo-
sure. Optical density of each band in the image was an-
alyzed via image collecting and analyzing software of
digital medical image analysis system.
Statistical analysis
Experimental data were expressed as mean±standard de-
viation ( xˉ ± s). Analysis was performed using SPSS
17.0 (SPSS Inc., Chicago, IL, USA) statistical software
package. One-way analysis of variance was applied to
the comparison of inter-group data. P<0.05 (P<0.01),
the difference between the two groups was significant
(or very significant) meaning.
RESULTS
Behaviors test
From day 3 of the five-day place navigation test, the D,
XL, XM and XH groups showed significant difference
in the mean escape latency and total swimming dis-
tance in comparison with M group (P<0.05, P<0.01)
(Table 1, 2). On day 5, all the treatment groups dem-
onstrated significant difference in the mean escape la-
tency and total swimming distance in comparison with
M group (P<0.01) (Table 1, 2). On day 6, all the treat-
ment groups displayed prolonged activity time in the
first quadrant in the space probe trial in comparison
with M group (P<0.05, P<0.01) (Table 3).
Western blot test result
Western blot test showed that level of O-GlcNAc glyco-
sylated proteins enriched by sWGA in M group was
significantly lower than that of S group (P<0.01).
Meanwhile, the O-GlcNAc glycosylation and expres-
sion of tau proteins in M group was significantly
lower than that of S group by RL2 and CTD110.6
test (P<0.01). Compared with M group, there were
marked improvement of O-GlcNAc glycosylation
and expression of tau proteins in XXD groups of dif-
ferent doses (P<0.05, P<0.01). There were no differ-
ences among XXD groups of different doses, and
there was also no significant difference between D
group and M group (Figure 1-3).
Group
S
M
D
XL
XM
XH
n
11
12
12
11
11
11
Day 1
77±25
95±7
79±24
69±42
57±20b
66±21b
Day 2
31±11
89±26a
67±26
61±29b
41±19c
27±10 c
Day 3
20±10
51±32a
28±17b
26±20b
27±21b
20±12c
Day 4
13±3
47±30a
28±26b
24±11b
31±28b
17±12c
Day 5
11±7
40±34a
16±14c
17±13c
20±23c
12±8c
Table 1 Comparison of mean escape latency in place navigation experiment of rats in each group (s, xˉ ±s)
Notes: S: sham-operation group; M: model group; D: donepezil group; XL: XXD low dose group; XM: XXD medium dose group; XH:
XXD high dose group. XXD: Xixin decoction. Compared with S group, aP<0.01; compared with M group, bP<0.05, cP<0.01.
Group
S
M
D
XL
XM
XH
n
11
12
12
11
11
11
Day 1
969±368
1211±304
1063±408
822±545a
743±313 a
969±400
Day 2
677±409
1093±498b
756±348a
666±494a
530±330c
422±205c
Day 3
334±175
764±376d
452±272a
328±174c
361±206c
342±172c
Day 4
334±175
749±376d
408±245a
317±146c
462±388a
252±123c
Day 5
179±106
602±409d
247±225c
261±216c
308±311c
157±105c
Table 2 Comparison of swimming distance in the place navigation test of rats in each group (cm, xˉ ±s)
Notes: S: sham-operation group; M: model group; D: donepezil group; XL: XXD low dose group; XM: XXD medium dose group; XH:
XXD high dose group. XXD: Xixin decoction. Compared with M group, aP<0.05, cP<0.01; compared with S group, bP<0.05, dP<0.01.
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Immunohistochemical detection
The immunohistochemical results were consistent with
the western blot method for detecting O-GlcNAc gly-
cosylation and expression of tau proteins in rats' hippo-
campal CA1 region with RL2. In comparison with S
group, the positive cell counts, total area of positive
cells as well as integral optical density were decreased
in M group (P<0.05, P<0.01). Positive cell counts, to-
tal area of positive cells as well as integral optical densi-
ty were all increased significantly in XL, XM and XH
groups compared with M group (P<0.05, P<0.01).
There were no marked difference among XXD groups,
and no significant difference between D group and M
group (Table 4, Figure 4A-F).
DISCUSSION
Recent researches showed that O-GlcNAc glycosyl-
ation played a vital role in the occurrence of Alzheimer
Figure 1 sWGA expression in the rat hippocampus among
different groups
A: representative immunoblot of sWGA expression; B: graph-
ic representation of relative abundance of sWGA normalized
toβ-actin. S: sham-operation group; M: model group; D:
donepezil group; XL: XXD low dose group; XM: XXD medi-
um dose group; XH: XXD high dose group. sWGA: succinylat-
ed wheat germ agglutinin. XXD: Xixin decoction. Data are
given as mean±SD. Compared with S group, aP<0.01; com-
pared with M group, bP<0.05, cP<0.01; compared with D
group, dP<0.05, eP<0.01.
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Figure 2 Tau RL2 expression in the rat hippocampus among
different groups
A: representative immunoblot of Tau RL2 expression; B:
graphic representation of relative abundance of RL2 normal-
ized to β-actin. S: sham-operation group; M: model group;
D: donepezil group; XL: XXD low dose group; XM: XXD medi-
um dose group; XH: XXD high dose group. XXD: Xixin decoc-
tion. Data are given as mean±SD. Compared with S group,
aP<0.01; compared with M group, bP<0.05, cP<0.01; com-
pared with D group, dP<0.05, eP<0.01.
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Figure 3 Tau CTD110.6 expression in the rat hippocampus
among different groups
A: representative immunoblot of Tau CTD110.6 expression;
B: graphic representation of relative abundance of Tau
CTD110.6 normalized to β-actin. S: sham-operation group;
M: model group; D: donepezil group; XL: XXD low dose
group; XM: XXD medium dose group; XH: XXD high dose
group. XXD: Xixin decoction. Data are given as mean± SD.
Compared with S group, aP<0.01; compared with M group,
bP<0.05,cP<0.01; compared with D group, dP<0.05, eP<0.01.
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Group
S
M
D
XL
XM
XH
n
11
12
12
11
11
11
Swimming time
59±9
16±6a
41±11b
40±14 b
53±4c
56±5c
Table 3 Comparison of swimming time around target quad-
rant of rats in each group (s, xˉ ±s)
Notes: S: sham-operation group; M: model group; D: donepezil
group; XL: XXD low dose group; XM: XXD medium dose
group; XH: XXD high dose group. XXD: Xixin decoction.
Compared with S group, aP<0.01; compared with M group, bP<
0.05, cP<0.01.
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disease.8 It is proved that during the process of SAD,
O-GlcNAc glycosylation directly regulated phosphory-
lation of tau proteins via Hexosamine biosynthetic
pathway.9 According to the theory of energy metabolic
disturbance in Alzheimer disease, neurofibril degenera-
tion induced by glucose intake and metabolic distur-
bance in the brain may constitute the major cause of
SAD.10 Glucose metabolic disturbance in AD patients'
brain affected the synthesis of UDP-GlcNAc, which
lowered O-GlcNAc glycosylation of tau proteins, caus-
ing hyperphosphorylation of tau proteins.8 Abnormal
hyperphosphorylation of tau proteins would not only
deprive tau protein of its normal biological activity, but
also turn it into cytotoxicity molecules, and force it to
deposit as NFT.11
Xixin decoction used in this experiment is an opti-
mized extract through rearrangement of ingredients
and doses of the famous formula prescribed by Shiduo
Chen in Qing Dynasty for treatment of dementia. Up-
on the treatment principle of replenishing Qi and rein-
Figure 4 Tau RL2 expression in CA1 region of hippocampus of rat by immunohistochemistry (×200)
A: S group: increased expression of positive cell count in the M group was detected with deeply stained cytoplasm; B: M group:
rare expression of positive cell counts; C: Donepezil group: rare expression of positive cell counts; D: XXD low dose group: in-
creased expression of positive cell count; E: XXD medium dose group: increased expression of positive cell count; F: XXD high
dose group: increased expression of positive cell count.
A B C
D E F
Group
S
M
D
XL
XM
XH
n
6
6
6
6
6
6
Positive cells count
84.8±0.3
18.4±0.9a
21.5±0.5
38.6±1.3bc
71.7±0.4de
74.4±1.8de
Total positive area (μm2)
32066.3±502.1
6797.3±117.6a
6906.1±61.8
11970.9±190.5dc
26514.5±450.5de
27445.2±316.0de
Integral optical density
172.0±0.6
56.2±1.2a
57.7±0.6
110.0±1.1dc
137.9±1.1de
140.9±2.9de
Table 4 Tau RL2 expression in CA1 region of hippocampus of rat by immunohistochemistry ( xˉ ±s)
Notes: S: sham-operation group; M: model group; D: donepezil group; XL: XXD low dose group; XM: XXD medium dose group; XH:
XXD high dose group.XXD: Xixin decoction. Compared with S group, aP<0.01; compared with M group, bP<0.05, dP<0.01; compared
with D group, cP<0.05, eP<0.01.
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forcing Yang, relieving stagnation and resolving
phlegm, the formula is intended for both resolving and
nourishing, taking both interior and exterior into con-
sideration, and has the functions of ascending Qi and
Yang, expelling Yin pathogenic factors, relieving stagna-
tion and resolving phlegm, as well as balancing Yin and
Yang. Pilot studies show that Xixin decoction can im-
prove spatial learning and memory ability of SAD rats'
by intracerebroventricular injection of streptozotocin,
with possible morphological basis related to the protec-
tion of hippocampal neuron mitochondrion and axo-
nal microtubule structure.7
This study showed that level of O-GlcNAc glycosylat-
ed proteins in M group was obviously lower than that
of S group. Meanwhile, RL2 and CTD110.6 test
showed that O-GlcNAc glycosylation and expression
of tau proteins in M group was significantly lower than
that of S group. These indicated that intracerebroven-
tricular injection of streptozotocin might have affected
energy metabolism and carbohydrate metabolism in
brain neurons, which lowered synthesis of acetylamino-
hexose, provider of O-GlcNAc glycosylation, leading
to decreased level of O-GlcNAc glycosylation of tau
proteins. This is in accordance with the case in SAD pa-
tients.12 In addition, the study demonstrates an increase
of O-GlcNAc glycosylated proteins enriched by sWGA
and expression of tau proteins detected by RL2 and
CTD110.6 in XXD groups of different doses in com-
parison with M group, which indicated that XXD
could improve the energy metabolism and carbohy-
drate metabolism in SAD rats' brain and increase the
level of O-GlcNAc glycosylation of tau proteins, thus
inhibit hyperphosphorylation of tau proteins as well as
its toxicity. Further study is expected to analyze the
mechanism, since this study is only the initial explor-
atory study of glycosylation modification on
O-GlcNAc.
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